Angle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects
Angle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects
Read moreFri, 21st Jun 2019 15:26
Angle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects
Read more(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that the liquid biopsy analysis unit at the Health Research Institute of Santiago in Spain has published results of new work undertaken in head and neck cancer and non small cell lung cancer, on the potential utility of a liquid biopsy-based strategy to assess MET alterations on circulating tumour cells (CTCs).
Read moreUK TRADING UPDATE SUMMARY: Zenith Latest To Join Global Drive For PPE
Read more(Sharecast News) - Biopharmaceuticals group Angle said on Tuesday that progress had been impeded by the Covid-19 outbreak as the firm worked with a research and development skeleton crew in Guildford.
Read moreUK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial
Read more(Sharecast News) - Liquid biopsy company Angle said on Tuesday that operations in the UK, US and Canada had all been "severely disrupted" by the Covid-19 pandemic.
Read moreAngle Parsortix Test Used To Help Discover Brain Metastasis
Read moreAngle's Parsortix Beats Others In Assessing Kidney Cancer Patients
Read more(Sharecast News) - Liquid biopsy company Angle announced on Thursday that Istituto Nazionale Tumori di Milano in Milan, Italy, has published results of work assessing the performance of its 'Parsortix' system in renal cell carcinoma (RCC), demonstrating key advantages of Parsortix.
Read more(Sharecast News) - Liquid biopsy company Angle announced on Monday that University Medical Centre Hamburg-Eppendorf has published results of work undertaken to assess the analytical and clinical performance of 'Parsortix' in multiple metastatic cancer types, with the main emphasis on metastatic breast cancer.
Read moreStudy Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival
Read more(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that a customer, the Edith Cowan University in Perth, Western Australia, has published results of research into the use of its 'Parsortix' system with melanoma patients.
Read moreAngle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreAngle Eyes US Consent For Parsortix Cancer Medication In Third Quarter
Read more